Among those tested, the most common tests administered during baseline were EGFR, molecular cytogenetics (FISH) for ALK or ROS-1, tumor immunochemistry panels (PD-1, PD-L1) and combination lung cancer panels (EGFR, KRAS, ALK, ROS-1, and PD-L1). This evidence concerns the gene KRAS and lung carcinoma.